Abbott Reports Late-Breaking Data of Amplatzer Amulet Device for Treating Patients with Atrial Fibrillation at Risk of Stroke
Shots:
- Abbott reports 5yrs. data of Amplatzer Amulet LAA Occluder for AFib patients at stroke risk, with the findings highlighted at AHA 2024 & published in the Journal of the American College of Cardiology
- The IDE study assessed Amplatzer Amulet vs Boston Scientific's Watchman device in >1,800 subjects and depicted reduction in the use of blood-thinning medications among 94% vs 90.9%, fewer fatal/disabling strokes (22 vs 39) and superior LAA closure (89.2% vs 83.3%)
- The Amplatzer Amulet is a closure device that prevents blood clot formation & leaving the LAA, reducing stroke risk in AFib patients. It further addresses the side-effects of blood-thinning medications like bleeding
Ref: Abbott | Image: Abbott
Related News: Abbott Reports 2 Years Data from the LIFE-BTK Study of Esprit BTK System to Treat Peripheral Artery Disease Below the Knee
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
